ALB and neoplasm: Together with a higher tumor absorbed dose, our data indicate a better tumor-to-salivary gland dose ratio for [177Lu]Lu-PSMA-ALB-56 (10.3 ± 8.3) as compared with [177Lu]Lu-PSMA-617 (2.7–9.0) [37, 38].